34
Participants
Start Date
August 31, 2017
Primary Completion Date
December 20, 2022
Study Completion Date
December 20, 2022
Ravulizumab
Participant received weight-based dosages for 26 weeks during the Initial Evaluation Period. Participants received a loading dose on Day 1, followed by maintenance dosing on Day 15 and once every 8 weeks thereafter for participants weighing ≥ 20 kg, or once every 4 weeks for participant weighing \< 20 kg.
Research Site, Brussels
Research Site, Barcelona
Research Site, Esplugues de Llobregat
Research Site, A Coruña
Research Site, Milan
Research Site, Charlotte
Research Site, Atlanta
Research Site, Hollywood
Research Site, Valencia
Research Site, Detroit
Research Site, Yangsan
Research Site, Jeju-do
Research Site, Omaha
Research Site, Heidelberg
Research Site, Hackensack
Research Site, Seoul
Research Site, Glasgow
Research Site, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY